Business

Cipla Signs Licence Agreement with Novartis AG; Will Manufacture Type-2 Diabetes Medicine From 2026

From January 2026, Cipla Limited will be manufacturing Galvus and Galvus combination brands that are used in the treatment of type 2 diabetes. The drug maker signed a perpetual license arrangement. Cipla in an agreement with Switzerland-based Novartis Pharma AG, the company said in an exchange filing on Monday. Up to that point, the business would keep producing and selling goods under the Galvus name.

“This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” it added.

The fulfilment of certain prerequisite requirements is a requirement for the agreement.

Read More: India remains top destination for Russian Urals oil

Galvus is a well-known brand in the oral diabetic treatment market and among the top brands in the Dipeptidyl Peptidase-4 (DPP4) market. With reported sales of Rs 268 crore, Galvus has the potential to considerably expand Cipla’s portfolio in the diabetes care continuum market. (IQVIA MAT February 2023).

This agreement is anticipated to strengthen Cipla’s standing as one of the leading companies in the diabetes market in India. The reflection of this was clearly seen in how shares on Cipla’s performance on Monday post the announcement. Shares of Cipla closed Monday’s trading session on the BSE 1.02% higher at Rs 901.85 a share.

The oral medication Galvus belongs to the Dipeptidyl Peptidase-4 (DPP4) class. Its reported sales of 268 crores are projected to strengthen Cipla’s position in the diabetic market, according to the statement. Decreasing prices are to be expected in the coming year.

The anti-diabetic medication Vildagliptin’s brand name and trademark rights for Vysov and Vysov M (Vildagliptin + Metformin) were purchased by Cipla in December 2019 for the Indian market. Under the trade names Vysov and Vysov M, the business had been co-marketing Vildagliptin in accordance with Novartis.

Read More: Kotak Mahindra Bank’s FPI Shareholding Crosses 25% Mark, MSCI Weightage Likely to Surge

 

 

Malika Sahni

Recent Posts

Maha Kumbh 2025: Yogi Government’s Strategic Coordination Ensures Timely Preparations

For Maha Kumbh 2025, preparations are in full swing as authorities work to ensure all…

10 hours ago

In Special Gesture, Kuwait’s Prime Minister Sees-Off PM Modi At Airport After Conclusion Of Historic Visit

Prime Minister Narendra Modi wrapped up his two-day visit to Kuwait on Sunday evening. In…

11 hours ago

Maha Kumbh 2025: Shri Panchdashnam Aawahan Akhara Makes Grand Entry Into Maha Kumbh City

Maha Kumbh 2025 with preparations for the Maha Sammelan are in full swing as 13…

11 hours ago

India’s Unifying Initiative: MRM Declares Bhagwat’s Message As The Foundation Of National Unity

The MRM strongly endorsed Rashtriya Swayamsevak Sangh (RSS) chief Mohan Bhagwat’s statement on temple-mosque disputes.…

11 hours ago

Maha Kumbh-2025: Prayagraj Mela Authority Deploys Advanced Sanitation Technology

For Maha Kumbh-2025, the Prayagraj Mela Authority has made extensive preparations to provide a clean…

13 hours ago

PM Narendra Modi To Attend Christmas Celebrations At CBCI In New Delhi

Prime Minister Narendra Modi is all set to attend the Christmas celebrations at CBCI Centre…

13 hours ago